Fibrotic Disease Models

Transforming growth factor beta signaling provides a biochemical cue that can activate fibrosis-related cellular behavior. In these models, it supports fibroblast-to-myofibroblast transition and encourages collagen-rich extracellular matrix formation. This makes the pathway useful for recreating key changes associated with scar development and for examining how candidate antifibrotic therapies affect cellular activation and matrix accumulation.

Mechanical cues help reproduce the physical environment associated with fibrotic tissue. As extracellular matrix accumulates and tissue becomes stiffer, cells experience conditions that differ from those in healthy tissue. Bioengineered systems can control these cues alongside biochemical signals, allowing researchers to examine how matrix stiffness and remodeling contribute to persistent tissue dysfunction.

Two-dimensional cultures provide a simpler setting for examining cell behavior and signaling, whereas three-dimensional matrices create a more tissue-like extracellular environment. The three-dimensional format can better represent matrix organization, collagen-rich surroundings, and mechanical conditions. Organoids and engineered tissues extend this approach by incorporating additional structural or cellular features relevant to organ-specific fibrosis.

A bioengineered system can combine relevant cells, biomaterials, and controlled biochemical or mechanical cues. Cells provide the biological response, while biomaterials establish the surrounding matrix environment. Researchers then adjust signaling or physical conditions to promote features such as fibroblast-to-myofibroblast transition, extracellular matrix deposition, and remodeling, creating a defined platform for mechanistic studies.

These models support investigation of how healthy tissue progresses toward stiffness, scarring, and dysfunction. They also provide platforms for evaluating antifibrotic therapies under controlled experimental conditions. Because the systems can reproduce selected cellular, biochemical, and matrix features of disease, they help connect mechanism-focused experiments with treatment testing and bioengineering research.

Fibrotic disease models can be developed for organs such as the lung, liver, heart, and kidney, allowing researchers to examine fibrosis in distinct tissue contexts. Organoids and engineered tissues are especially useful for building more physiologically relevant platforms. These systems may also support precision medicine by enabling disease and treatment responses to be studied in tailored experimental environments.